Nasus Pharma Ltd., a clinical-stage pharmaceutical company focused on developing intranasal products for emergency medical conditions, has priced its initial public offering (IPO) of 1,250,000 ordinary shares at $8.00 per share, raising gross proceeds of $10 million. The company also granted the underwriters an option to purchase up to an additional 187,500 ordinary shares within 45 days to cover any over-allotment. The IPO is expected to close on August 14, 2025, subject to customary closing conditions, with shares beginning trading on the NYSE American under the ticker symbol NSRX.

Nasus Pharma plans to use the net proceeds to advance its intranasal epinephrine program, including manufacturing scale-up and additional Phase 2 studies. The remainder of the funds will support general corporate purposes such as working capital and capital expenditures. These resources aim to accelerate the development of rapid-acting emergency therapies that could improve outcomes for patients experiencing acute medical conditions.

Joint bookrunners for the offering are Laidlaw & Company (UK) Ltd. and Craft Capital Management LLC. The IPO follows the Securities and Exchange Commission’s (SEC) declaration of effectiveness of Nasus Pharma’s Form F-1 registration statement (File No. 333-288582). The company emphasized that this announcement does not constitute an offer to sell or solicitation to buy securities in jurisdictions where such activities would be unlawful.

Intranasal delivery systems are gaining attention in pharmaceutical development due to their potential to provide rapid, non-invasive administration of critical medications. For emergency interventions such as anaphylaxis or other acute conditions, speed and ease of administration can significantly impact patient outcomes. Nasus Pharma’s approach aims to combine fast-acting formulations with scalable manufacturing to improve accessibility and reliability.

As a clinical-stage company, Nasus Pharma is focused on rigorous testing of its pipeline candidates to ensure both safety and efficacy. The IPO proceeds will allow continued investment in Phase 2 trials, which are designed to assess efficacy in patient populations under controlled clinical conditions. This is a critical stage for potential regulatory submissions and eventual commercialization.

By securing this funding, Nasus Pharma positions itself to advance its intranasal therapies and strengthen its pipeline, reflecting broader trends in pharmaceutical innovation where non-invasive delivery methods are increasingly used to improve patient adherence and clinical outcomes.